News
Company News: Curetis subsidiary Ares Genetics wins incubator stay in Silicon Valley
— Award winner in “GoSiliconValley” competition by Austrian Economic Chambers
— Support for business development in U.S. market
Curetis N.V. (the “Company” and, together with Curetis USA Inc. and Curetis GmbH, “Curetis“), a developer of next-level molecular diagnostic solutions, today announced that its wholly-owned subsidiary Ares Genetics GmbH (Vienna, Austria) has been selected as a winner of the “GoSiliconValley” competition of the Austrian Economic Chambers (WKO).
Company News: ISA Pharmaceuticals and Scancell enter collaboration agreement for the manufacturing, development and commercialisation of Modi-1 / AMPLIVANT® combination
— AMPLIVANT-Modi-1 conjugate expected to enter clinic in H1 2019
— Collaboration seeks to further leverage Moditope® platform
ISA Pharmaceuticals B.V. (‘ISA’), a clinical-stage immunotherapy company, and Scancell Holdings plc, (‘Scancell’ or the ‘Company’), the developer of novel immunotherapies for the treatment of cancer, are pleased to announce that they have entered into a worldwide licensing and collaboration agreement to use ISA’s AMPLIVANT® adjuvant technology for the manufacturing, development and commercialisation of Scancell’s first Moditope® development candidate, Modi-1.
Company News: TRON receives three-year research grant from the Falconwood Foundation to develop new treatment approaches for neuroendocrine tumors
TRON (Translational Oncology at the University Medical Center of the Johannes Gutenberg University Mainz, Germany), an internationally recognized leader in tumor immunology and cancer therapy research, has announced a three-year grant from the Falconwood Foundation, New York, USA, totalling 3 Million Euros. The grant supports the launch of a new research project to identify biomarkers specific for neuroendocrine tumors (NETs) that are crucial for the development of new, personalized immunotherapies to treat NET patients.
Company News: Curetis´ Unyvero HPN Application Receives Singapore Health Sciences Authority Approval; Updates on Sepsis Host Response Test
— Market authorization paves way for broader Unyvero commercial roll-out in ASEAN region through partner Acumen Research Laboratories
— Near-term clinical validation study of first cartridge-based molecular test for Sepsis Host Response panel licensed from Acumen in preparation
Curetis N.V. (the “Company” and, together with Curetis GmbH, “Curetis“), a developer of next-level molecular diagnostic solutions, today announced that Acumen Research Laboratories Pte Ltd. (Acumen), its partner for the commercialization of Unyvero in the ASEAN region, has received approval by the Singapore Health Sciences Authority (HSA) to market the Unyvero HPN Hospitalized Pneumonia Application Cartridge in Singapore.